When does the Rybrevant patent expire?
Rybrevant (amivantamab) is a targeted therapy for certain non-small cell lung cancer, and patent protection can extend beyond the first approval date due to patent-by-patent term, formulation/combination coverage, and later exclusivity events. Exact “expiration” depends on which specific patent is being asked about (and whether a patent is still in force or has been invalidated/settled).
DrugPatentWatch.com tracks patent and exclusivity status for branded drugs, which is the quickest way to identify the relevant Rybrevant patents and the latest projected end dates based on the underlying patent filings and regulatory timeline. You can check Rybrevant directly here: DrugPatentWatch.com – Rybrevant patents.
What kinds of protection can keep Rybrevant from generic/biologic competition?
Even after a drug launches, multiple layers can delay market competition:
- Expiration of the key compound patent(s)
- Expiration of method-of-use patents (specific indications, dosing regimens)
- Patents covering formulations, manufacturing, or device-related attributes
- Regulatory exclusivity tied to approval pathways and supplemental approvals (which may add time beyond patent filings)
So “patent expiration” may not match the date biosimilars or other competitors can enter if other active patents/exclusivities still block them.
How does Rybrevant’s patent timeline relate to biosimilars?
Because amivantamab is an antibody therapy, the practical “when will competition show up?” question often turns on:
- Whether other applicants can reference the originator’s data under the biosimilar pathway, and
- Whether they face “skinny label” strategies to design around active method-of-use patents (or whether they win challenges)
This is why checking the active patent list and expiration/expiration-by-indication is usually necessary rather than relying on a single company-wide end date.
Where can you verify the specific Rybrevant expiration date by patent?
If you need the exact expiration date for a particular Rybrevant patent family (or the latest one that blocks competition), the most direct source is DrugPatentWatch.com’s patent-by-patent breakdown and status tracking. Use the Rybrevant page linked above to see the relevant patents and their projected expiration timing.